InvestorsHub Logo
Followers 468
Posts 26893
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 113

Monday, 10/10/2011 6:00:55 PM

Monday, October 10, 2011 6:00:55 PM

Post# of 124
Focus On Entereg; Reiterating Buy On Adolor

http://seekingalpha.com/article/293795-focus-on-entereg-reiterating-buy-on-adolor?source=yahoo

I upgraded Adolor (ADLR) to a BUY after the company announced that it had reacquired all rights to Entereg from GlaxoSmithKline (GSK). I did this even though binary phase II data on ADL 5945, its new drug for opioid induced constipation, was due at any time. I felt that the stock was attractive on the basis of Entereg alone, and this induced me to take the risk of being in front of an important data release. I was holding my breath, but fortunately of phase II data on ADL 5945 was very positive.

I am now carefully watching two key events to see how they unfold:

The transition of Entereg from a co-marketing agreement with Glaxo to Adolor assuming all responsibility for marketing.
The second key event is the progress of partnering discussions on ADL 5945. I recently attended an investor conference and spoke with Adolor’s management on these two issues. I was encouraged by their responses and I am reiterating my Buy recommendation.


surf's up......crikey